查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1223492

子宫癌症诊断的全球市场 - 产业趋势与预测(～2030年)

Global Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 900 Pages | 商品交期: 请询问到货日

价格

全球子宫癌症诊断的市场规模，2023年～2030年的预测期间预计以10.7％的年复合成长率成长。女性的子宫癌症患者增加，子宫癌症诊断的技术进步，推动市场成长。

本报告提供全球子宫癌症诊断市场相关调查分析，产业趋势与预测，市场区隔分析，企业简介等资讯。

目录

第1章 简介

第2章 市场区隔

第3章 摘要整理

第4章 主要考察

  • PESTEL分析
  • 波特的五力分析
  • 全球子宫癌症诊断市场专利分析
  • 偿付情境
  • 产业的考察
  • 人口动态趋势:全发生率的影响
  • 价格策略
  • 结论
  • 子宫癌症的盛行率，发生率，死亡率
  • 子宫癌症治疗的费用

第5章 法律规范

第6章 市场概要

  • 促进因素
  • 阻碍因素
  • 机会
  • 课题

第7章 全球子宫癌症诊断市场:各诊断类型

  • 概要
  • 器具为基础
    • 超音波扫瞄
    • 影像装置
    • 检验
    • 其他
  • 治疗为基础
    • 子宫内膜切片检查
    • 子宫镜检查
    • 扩张，刮宫术
    • 膀胱镜子检验
    • 直肠镜子检验
    • 其他

第8章 全球子宫癌症诊断市场:各类型

  • 概要
  • 子宫内膜癌症
    • 浆液性腺癌症
    • 腺扁平表皮癌症
    • 子宫癌症肉瘤
    • 子宫内膜核电站扁平表皮癌症
  • 子宫肉瘤
    • 平滑肌肉瘤
    • 子宫内膜间质肉瘤
    • 未分化肉瘤

第9章 全球子宫癌症诊断市场:各年龄层

  • 概要
  • 60岁以上
  • 51-60岁
  • 41-50岁
  • 31-40岁
  • 不满30岁

第10章 全球子宫癌症诊断市场:各终端用户

  • 概要
  • 医院
  • 诊断中心
  • 癌症研究中心
  • 门诊病人手术中心
  • 专门诊所
  • 其他

第11章 全球子宫癌症诊断市场:各流通管道

  • 概要
  • 直接提供
  • 第三方销售商
  • 其他

第12章 全球子宫癌症诊断市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 荷兰
    • 波兰
    • 瑞士
    • 比利时
    • 瑞典
    • 挪威
    • 丹麦
    • 芬兰
    • 土耳其
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 台湾
    • 纽西兰
    • 韩国
    • 新加坡
    • 印尼
    • 菲律宾
    • 越南
    • 泰国
    • 马来西亚
    • 其他的亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中东、非洲
    • 南非
    • 沙乌地阿拉伯
    • 巴林
    • 阿拉伯联合大公国
    • 埃及
    • 以色列
    • 科威特
    • 阿曼
    • 卡达
    • 其他的中东、非洲

第13章 全球子宫癌症诊断市场，企业形势

  • 企业占有率分析:世界
  • 企业占有率分析:北美
  • 企业占有率分析:欧洲
  • 企业占有率分析:亚太地区

第14章 SWOT分析

The global uterine cancer diagnostics market is projected to register a CAGR of 10.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based and Procedure Based), Type (Endometrial Cancer and Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centres, Cancer Research Centre, Ambulatory Surgical Centres, Specialized Clinics, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, Rest of Europe, Japan, China, South Korea, India, Australia, New Zealand, Hong Kong, Taiwan, Singapore, Thailand, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, South Africa, UAE., Saudi Arabia, Kuwait, Rest of the Middle East and Africa, Brazil, Argentina, Venezuela and Rest of South America) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Global uterine cancer diagnostics market are:

Increasing uterine cancer patients among the women population

Rise in technological advancement for uterine cancer diagnosis

Market Players

Some of the key market players operating in the global uterine cancer diagnostics market are:

F-Hoffmann La Roche Ltd.

Siemens Healthcare Private Limited

Narang Medical Limited

ESAOTE SPA

Olympus Corporation

Arquer Diagnostics Ltd

Guzip Biomarkers Corporation

General Electric Company

Canon Medical Systems ANZ Pty Limited

KARL STORZ SE & Co. KG

Medtronic

Stryker

Surtex Instruments Limited

Koninklijke Philips N.V.

FUJIFILM Corporation

AED.MD

Jalal Surgical

Integra LifeSciences

B. Braun Melsungen AG

GRAIL

TABLE OF CONTENTS

1 INTRODUCTION 118

  • 1.1 OBJECTIVES OF THE STUDY 118
  • 1.2 MARKET DEFINITION 118
  • 1.3 OVERVIEW OF THE GLOBAL UTERINE CANCER DIAGNOSTIC MARKET 118
  • 1.4 CURRENCY AND PRICING 120
  • 1.5 LIMITATIONS 120
  • 1.6 MARKETS COVERED 120

2 MARKET SEGMENTATION 128

  • 2.1 MARKETS COVERED 128
  • 2.2 GEOGRAPHICAL SCOPE 129
  • 2.3 YEARS CONSIDERED FOR THE STUDY 130
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 131
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
  • 2.6 MULTIVARIATE MODELLING 135
  • 2.7 MARKET APPLICATION COVERAGE GRID 136
  • 2.8 INSTRUMENT BASED LIFELINE CURVE 137
  • 2.9 DBMR MARKET POSITION GRID 138
  • 2.10 VENDOR SHARE ANALYSIS 140
  • 2.11 SECONDARY SOURCES 141
  • 2.12 ASSUMPTIONS 141

3 EXECUTIVE SUMMARY 142

4 PREMIUM INSIGHTS 145

  • 4.1 PESTEL ANALYSIS 148
  • 4.2 PORTER'S FIVE FORCES 149
  • 4.3 PATENT ANALYSIS OF GLOBAL UTERINE CANCER DIAGNOSTICS MARKET 150
  • 4.4 REIMBURSEMENT SCENARIO 151
  • 4.5 INDUSTRY INSIGHTS: 152
  • 4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 152
  • 4.7 PRICING STRATEGIES 152
  • 4.8 CONCLUSION 153
  • 4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER 154
  • 4.10 COST OF UTERINE CANCER PROCEDURE 156

5 REGULATORY FRAMEWORK 157

6 MARKET OVERVIEW 159

  • 6.1 DRIVERS 161
    • 6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS 161
    • 6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES 161
    • 6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER 162
    • 6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH 162
  • 6.2 RESTRAINTS 163
    • 6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS 163
    • 6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER 163
  • 6.3 OPPORTUNITIES 164
    • 6.3.1 INCREASING PREVALENCE OF UTERINE CANCER 164
    • 6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE 164
    • 6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS 165
  • 6.4 CHALLENGES 165
    • 6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 165
    • 6.4.2 HIGH COST OF IMAGING SYSTEMS 166

7 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 167

  • 7.1 OVERVIEW 168
  • 7.2 INSTRUMENT-BASED 171
    • 7.2.1 ULTRASOUND SCANNING 172
      • 7.2.1.1 SYSTEMS 172
      • 7.2.1.2 ABDOMINAL ULTRASOUND SCANNING 173
      • 7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING 173
      • 7.2.1.4 ACCESSORIES 173
    • 7.2.2 IMAGING DEVICES 173
      • 7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN 174
      • 7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI) 174
      • 7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN 174
      • 7.2.2.4 OTHERS 174
    • 7.2.3 TESTS 175
      • 7.2.3.1 BLOOD TESTS 175
        • 7.2.3.1.1 COMPLETE BLOOD COUNT 175
        • 7.2.3.1.2 CA125 MARKER BLOOD TEST 175
      • 7.2.3.2 URINE TESTS 176
      • 7.2.3.3 OTHER TESTS 176
    • 7.2.4 OTHERS 176
  • 7.3 PROCEDURE BASED 176
    • 7.3.1 ENDOMETRIAL BIOPSY 177
    • 7.3.2 HYSTEROSCOPY 177
    • 7.3.3 DILATION & CURETTAGE 177
    • 7.3.4 CYSTOSCOPY 177
    • 7.3.5 PROCTOSCOPY 178
    • 7.3.6 OTHERS 178

8 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE 179

  • 8.1 OVERVIEW 180
  • 8.2 ENDOMETRIAL CANCER 183
    • 8.2.1 SEROUS ADENOCARCINOMA 184
      • 8.2.1.1 INSTRUMENT-BASED 184
        • 8.2.1.1.1 ULTRASOUND SCANNING 185
        • 8.2.1.1.2 IMAGING DEVICES 185
        • 8.2.1.1.3 TESTS 185
        • 8.2.1.1.4 OTHERS 185
      • 8.2.1.2 PROCEDURE-BASED 186
        • 8.2.1.2.1 ENDOMETRIAL BIOPSY 186
        • 8.2.1.2.2 HYSTEROSCOPY 186
        • 8.2.1.2.3 DILATION & CURETTAGE 186
        • 8.2.1.2.4 CYSTOSCOPY 186
        • 8.2.1.2.5 PROCTOSCOPY 186
        • 8.2.1.2.6 OTHERS 187
    • 8.2.2 ADENOSQUAMOUS CARCINOMA 187
      • 8.2.2.1 INSTRUMENT-BASED 187
        • 8.2.2.1.1 ULTRASOUND SCANNING 187
        • 8.2.2.1.2 IMAGING DEVICES 188
        • 8.2.2.1.3 TESTS 188
        • 8.2.2.1.4 OTHERS 188
      • 8.2.2.2 PROCEDURE-BASED 188
        • 8.2.2.2.1 ENDOMETRIAL BIOPSY 188
        • 8.2.2.2.2 HYSTEROSCOPY 188
        • 8.2.2.2.3 DILATION & CURETTAGE 189
        • 8.2.2.2.4 CYSTOSCOPY 189
        • 8.2.2.2.5 PROCTOSCOPY 189
        • 8.2.2.2.6 OTHERS 189
    • 8.2.3 UTERINE CARCINOSARCOMA 189
      • 8.2.3.1 INSTRUMENT-BASED 189
        • 8.2.3.1.1 ULTRASOUND SCANNING 190
        • 8.2.3.1.2 IMAGING DEVICES 190
        • 8.2.3.1.3 TESTS 190
        • 8.2.3.1.4 OTHERS 190
      • 8.2.3.2 PROCEDURE-BASED 191
        • 8.2.3.2.1 ENDOMETRIAL BIOPSY 191
        • 8.2.3.2.2 HYSTEROSCOPY 191
        • 8.2.3.2.3 DILATION & CURETTAGE 191
        • 8.2.3.2.4 CYSTOSCOPY 191
        • 8.2.3.2.5 PROCTOSCOPY 191
        • 8.2.3.2.6 OTHERS 192
    • 8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM 192
      • 8.2.4.1 INSTRUMENT-BASED 192
        • 8.2.4.1.1 ULTRASOUND SCANNING 192
        • 8.2.4.1.2 IMAGING DEVICES 193
        • 8.2.4.1.3 TESTS 193
        • 8.2.4.1.4 OTHERS 193
      • 8.2.4.2 PROCEDURE-BASED 193
        • 8.2.4.2.1 ENDOMETRIAL BIOPSY 193
        • 8.2.4.2.2 HYSTEROSCOPY 193
        • 8.2.4.2.3 DILATION & CURETTAGE 194
        • 8.2.4.2.4 CYSTOSCOPY 194
        • 8.2.4.2.5 PROCTOSCOPY 194
        • 8.2.4.2.6 OTHERS 194
  • 8.3 UTERINE SARCOMA 194
    • 8.3.1 LEIOMYOSARCOMA 195
      • 8.3.1.1 INSTRUMENT-BASED 195
        • 8.3.1.1.1 ULTRASOUND SCANNING 196
        • 8.3.1.1.2 IMAGING DEVICES 196
        • 8.3.1.1.3 TESTS 196
        • 8.3.1.1.4 OTHERS 196
      • 8.3.1.2 PROCEDURE-BASED 197
        • 8.3.1.2.1 ENDOMETRIAL BIOPSY 197
        • 8.3.1.2.2 HYSTEROSCOPY 197
        • 8.3.1.2.3 DILATION & CURETTAGE 197
        • 8.3.1.2.4 CYSTOSCOPY 197
        • 8.3.1.2.5 PROCTOSCOPY 197
        • 8.3.1.2.6 OTHERS 198
    • 8.3.2 ENDOMETRIAL STROMAL SARCOMA 198
      • 8.3.2.1 INSTRUMENT-BASED 198
        • 8.3.2.1.1 ULTRASOUND SCANNING 198
        • 8.3.2.1.2 IMAGING DEVICES 199
        • 8.3.2.1.3 TESTS 199
        • 8.3.2.1.4 OTHERS 199
      • 8.3.2.2 PROCEDURE-BASED 199
        • 8.3.2.2.1 ENDOMETRIAL BIOPSY 199
        • 8.3.2.2.2 HYSTEROSCOPY 199
        • 8.3.2.2.3 DILATION & CURETTAGE 200
        • 8.3.2.2.4 CYSTOSCOPY 200
        • 8.3.2.2.5 PROCTOSCOPY 200
        • 8.3.2.2.6 OTHERS 200
    • 8.3.3 UNDIFFERENTIATED SARCOMA 200
      • 8.3.3.1 INSTRUMENT-BASED 201
        • 8.3.3.1.1 ULTRASOUND SCANNING 201
        • 8.3.3.1.2 IMAGING DEVICES 201
        • 8.3.3.1.3 TESTS 201
        • 8.3.3.1.4 OTHERS 201
      • 8.3.3.2 PROCEDURE-BASED 202
        • 8.3.3.2.1 ENDOMETRIAL BIOPSY 202
        • 8.3.3.2.2 HYSTEROSCOPY 202
        • 8.3.3.2.3 DILATION & CURETTAGE 202
        • 8.3.3.2.4 CYSTOSCOPY 202
        • 8.3.3.2.5 PROCTOSCOPY 203
        • 8.3.3.2.6 OTHERS 203

9 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 204

  • 9.1 OVERVIEW 205
  • 9.2 >60 YEARS 208
  • 9.3 51-60 YEARS 209
  • 9.4 41-50 YEARS 210
  • 9.5 31-40 YEARS 211
  • 9.6 <30 YEARS 212

10 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY END USER 213

  • 10.1 OVERVIEW 214
  • 10.2 HOSPITALS 217
  • 10.3 DIAGNOSTIC CENTERS 218
  • 10.4 CANCER RESEARCH CENTERS 219
  • 10.5 AMBULATORY SURGICAL CENTERS 220
  • 10.6 SPECIALIZED CLINICS 221
  • 10.7 OTHERS 222

11 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 223

  • 11.1 OVERVIEW 224
  • 11.2 DIRECT TENDER 227
  • 11.3 THIRD PARTY DISTRIBUTORS 228
  • 11.4 OTHERS 229

12 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY REGION 230

  • 12.1 OVERVIEW 231
  • 12.2 NORTH AMERICA 236
    • 12.2.1 U.S. 252
    • 12.2.2 CANADA 263
    • 12.2.3 MEXICO 274
  • 12.3 EUROPE 287
    • 12.3.1 GERMANY 303
    • 12.3.2 FRANCE 314
    • 12.3.3 UNITED KINGDOM 326
    • 12.3.4 ITALY 339
    • 12.3.5 SPAIN 351
    • 12.3.6 RUSSIA 362
    • 12.3.7 NETHERLANDS 375
    • 12.3.8 POLAND 388
    • 12.3.9 SWITZERLAND 401
    • 12.3.10 BELGIUM 414
    • 12.3.11 SWEDEN 427
    • 12.3.12 NORWAY 440
    • 12.3.13 DENMARK 453
    • 12.3.14 FINLAND 466
    • 12.3.15 TURKEY 479
    • 12.3.16 REST OF EUROPE 492
  • 12.4 ASIA-PACIFIC 493
    • 12.4.1 CHINA 510
    • 12.4.2 JAPAN 523
    • 12.4.3 INDIA 536
    • 12.4.4 AUSTRALIA 549
    • 12.4.5 TAIWAN 562
    • 12.4.6 NEW ZEALAND 575
    • 12.4.7 SOUTH KOREA 588
    • 12.4.8 SINGAPORE 601
    • 12.4.9 INDONESIA 614
    • 12.4.10 PHILIPPINES 627
    • 12.4.11 VIETNAM 640
    • 12.4.12 THAILAND 653
    • 12.4.13 MALAYSIA 665
    • 12.4.14 REST OF ASIA PACIFIC 678
  • 12.5 SOUTH AMERICA 679
    • 12.5.1 BRAZIL 696
    • 12.5.2 ARGENTINA 709
    • 12.5.3 REST OF SOUTH AMERICA 721
  • 12.6 MIDDLE EAST AND AFRICA 722
    • 12.6.1 SOUTH AFRICA 739
    • 12.6.2 SAUDI ARABIA 752
    • 12.6.3 BAHRAIN 765
    • 12.6.4 UAE 778
    • 12.6.5 EGYPT 790
    • 12.6.6 ISRAEL 803
    • 12.6.7 KUWAIT 816
    • 12.6.8 OMAN 829
    • 12.6.9 QATAR 842
    • 12.6.10 REST OF MIDDLE EAST AND AFRICA 855

13 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 856

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL 856
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 857
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE 858
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 859

14 SWOT ANALYSIS 860

15 COMPANY PROFILE 861

  • 15.1 KONINKLIJKE PHILIPS N.V. 861
    • 15.1.1 COMPANY SNAPSHOT 861
    • 15.1.2 REVENUE ANALYSIS 861
    • 15.1.3 COMPANY SHARE ANALYSIS 862
    • 15.1.4 PRODUCT PORTFOLIO 862
    • 15.1.5 RECENT DEVELOPMENTS 862
  • 15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED. 864
    • 15.2.1 COMPANY SNAPSHOT 864
    • 15.2.2 COMPANY SHARE ANALYSIS 864
    • 15.2.3 PRODUCT PORTFOLIO 865
    • 15.2.4 RECENT DEVELOPMENTS 865
  • 15.3 GENERAL ELECTRIC COMPANY 866
    • 15.3.1 COMPANY SNAPSHOT 866
    • 15.3.2 REVENUE ANALYSIS 866
    • 15.3.3 COMPANY SHARE ANALYSIS 867
    • 15.3.4 PRODUCT PORTFOLIO 867
    • 15.3.5 RECENT DEVELOPMENTS 867
  • 15.4 SIEMENS HEALTHCARE GMBH 869
    • 15.4.1 COMPANY SNAPSHOT 869
    • 15.4.2 REVENUE ANALYSIS 869
    • 15.4.3 COMPANY SHARE ANALYSIS 870
    • 15.4.4 PRODUCT PORTFOLIO 870
    • 15.4.5 RECENT DEVELOPMENTS 870
  • 15.5 FUJIFILM CORPORATION 871
    • 15.5.1 COMPANY SNAPSHOT 871
    • 15.5.2 REVENUE ANALYSIS 871
    • 15.5.3 COMPANY SHARE ANALYSIS 872
    • 15.5.4 PRODUCT PORTFOLIO 872
    • 15.5.5 RECENT DEVELOPMENTS 872
  • 15.6 AED.MD 874
    • 15.6.1 COMPANY SNAPSHOT 874
    • 15.6.2 PRODUCT PORTFOLIO 874
    • 15.6.3 RECENT DEVELOPMENTS 874
  • 15.7 ARQUER DIAGNOSTICS LTD 875
    • 15.7.1 COMPANY SNAPSHOT 875
    • 15.7.2 PRODUCT PORTFOLIO 875
    • 15.7.3 RECENT DEVELOPMENTS 875
  • 15.8 B. BRAUN SE 876
    • 15.8.1 COMPANY SNAPSHOT 876
    • 15.8.2 PRODUCT PORTFOLIO 876
    • 15.8.3 RECENT DEVELOPMENTS 876
  • 15.9 ESAOTE SPA 877
    • 15.9.1 COMPANY SNAPSHOT 877
    • 15.9.2 PRODUCT PORTFOLIO 877
    • 15.9.3 RECENT DEVELOPMENTS 877
  • 15.10 F. HOFFMANN-LA ROCHE LTD 879
    • 15.10.1 COMPANY SNAPSHOT 879
    • 15.10.2 REVENUE ANALYSIS 879
    • 15.10.3 PRODUCT PORTFOLIO 880
    • 15.10.4 RECENT DEVELOPMENTS 880
  • 15.11 GRAIL 881
    • 15.11.1 COMPANY SNAPSHOT 881
    • 15.11.2 PRODUCT PORTFOLIO 881
    • 15.11.3 RECENT DEVELOPMENTS 881
  • 15.12 GUZIP BIOMARKERS CORPORATION 883
    • 15.12.1 COMPANY SNAPSHOT 883
    • 15.12.2 PRODUCT PORTFOLIO 883
    • 15.12.3 RECENT DEVELOPMENTS 883
  • 15.13 INTEGRA LIFESCIENCES 884
    • 15.13.1 COMPANY SNAPSHOT 884
    • 15.13.2 REVENUE ANALYSIS 884
    • 15.13.3 PRODUCT PORTFOLIO 885
    • 15.13.4 RECENT DEVELOPMENTS 885
  • 15.14 JALAL SURGICAL 886
    • 15.14.1 COMPANY SNAPSHOT 886
    • 15.14.2 PRODUCT PORTFOLIO 886
    • 15.14.3 RECENT DEVELOPMENTS 886
  • 15.15 KARL STORZ SE & CO. KG 887
    • 15.15.1 COMPANY SNAPSHOT 887
    • 15.15.2 PRODUCT PORTFOLIO 887
    • 15.15.3 RECENT DEVELOPMENTS 888
  • 15.16 MEDTRONIC 889
    • 15.16.1 COMPANY SNAPSHOT 889
    • 15.16.2 REVENUE ANALYSIS 889
    • 15.16.3 PRODUCT PORTFOLIO 890
    • 15.16.4 RECENT DEVELOPMENTS 890
  • 15.17 NARANG MEDICAL LIMITED 891
    • 15.17.1 COMPANY SNAPSHOT 891
    • 15.17.2 PRODUCT PORTFOLIO 891
    • 15.17.3 RECENT DEVELOPMENTS 891
  • 15.18 OLYMPUS CORPORATION 892
    • 15.18.1 COMPANY SNAPSHOT 892
    • 15.18.2 REVENUE ANALYSIS 892
    • 15.18.3 PRODUCT PORTFOLIO 893
    • 15.18.4 RECENT DEVELOPMENTS 893
  • 15.19 STRYKER 894
    • 15.19.1 COMPANY SNAPSHOT 894
    • 15.19.2 REVENUE ANALYSIS 894
    • 15.19.3 PRODUCT PORTFOLIO 895
    • 15.19.4 RECENT DEVELOPMENTS 895
  • 15.20 SURTEX INSTRUMENTS LIMITED. 896
    • 15.20.1 COMPANY SNAPSHOT 896
    • 15.20.2 PRODUCT PORTFOLIO 896
    • 15.20.3 RECENT DEVELOPMENTS 896

16 QUESTIONNAIRE 897

17 RELATED REPORTS 900

LIST OF TABLES

  • TABLE 1 GLOBAL RATE OF ENDOMETRIAL CANCER (2020) 154
  • TABLE 2 U.S. (2022) 154
  • TABLE 3 U.K. (2019) 154
  • TABLE 4 GERMANY RATE OF ENDOMETRIAL CANCER (2019) 154
  • TABLE 5 POLAND RATE OF ENDOMETRIAL CANCER (2020) 154
  • TABLE 6 SINGAPORE (2020) 154
  • TABLE 7 JAPAN (2022) 154
  • TABLE 8 INDIA (2020) 155
  • TABLE 9 AUSTRALIA (2022) 155
  • TABLE 10 BRAZIL RATE OF ENDOMETRIAL CANCER (2018) 155
  • TABLE 11 ARGENTINA (2020) 155
  • TABLE 12 UAE (2020) 155
  • TABLE 13 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 14 GLOBAL INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 171
  • TABLE 15 GLOBAL INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 16 GLOBAL ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 17 GLOBAL ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 172
  • TABLE 18 GLOBAL SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 172
  • TABLE 19 GLOBAL SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 173
  • TABLE 20 GLOBAL IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 173
  • TABLE 21 GLOBAL IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 174
  • TABLE 22 GLOBAL TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 23 GLOBAL BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 175
  • TABLE 24 GLOBAL PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 176
  • TABLE 25 GLOBAL PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 26 GLOBAL PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 177
  • TABLE 27 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
  • TABLE 28 GLOBAL ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 183
  • TABLE 29 GLOBAL ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 30 GLOBAL SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 184
  • TABLE 31 GLOBAL INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 185
  • TABLE 32 GLOBAL PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 186
  • TABLE 33 GLOBAL ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 34 GLOBAL INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 187
  • TABLE 35 GLOBAL PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 188
  • TABLE 36 GLOBAL UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 189
  • TABLE 37 GLOBAL INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 190
  • TABLE 38 GLOBAL PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 191
  • TABLE 39 GLOBAL PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 192
  • TABLE 40 GLOBAL INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 192
  • TABLE 41 GLOBAL PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 193
  • TABLE 42 GLOBAL UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 194
  • TABLE 43 GLOBAL UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 44 GLOBAL LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 195
  • TABLE 45 GLOBAL INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 196
  • TABLE 46 GLOBAL PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 197
  • TABLE 47 GLOBAL ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 198
  • TABLE 48 GLOBAL INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 198
  • TABLE 49 GLOBAL PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 199
  • TABLE 50 GLOBAL UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 200
  • TABLE 51 GLOBAL INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 201
  • TABLE 52 GLOBAL PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 202
  • TABLE 53 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 207
  • TABLE 54 GLOBAL >60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 208
  • TABLE 55 GLOBAL 51-60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 209
  • TABLE 56 GLOBAL 41-50 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 210
  • TABLE 57 GLOBAL 31-40 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 211
  • TABLE 58 GLOBAL <30 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 212
  • TABLE 59 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 216
  • TABLE 60 GLOBAL HOSPITALS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 217
  • TABLE 61 GLOBAL DIAGNOSTIC CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 218
  • TABLE 62 GLOBAL CANCER RESEARCH CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 219
  • TABLE 63 GLOBAL AMBULATORY SURGICAL CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 220
  • TABLE 64 GLOBAL SPECIALIZED CLINICS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 221
  • TABLE 65 GLOBAL OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 222
  • TABLE 66 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 226
  • TABLE 67 GLOBAL DIRECT TENDER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 227
  • TABLE 68 GLOBAL THIRD PARTY DISTRIBUTORS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 228
  • TABLE 69 GLOBAL OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 229
  • TABLE 70 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 235
  • TABLE 71 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 240
  • TABLE 72 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 240
  • TABLE 73 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 240
  • TABLE 74 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 240
  • TABLE 75 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 241
  • TABLE 76 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 241
  • TABLE 77 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 78 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 241
  • TABLE 79 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 241
  • TABLE 80 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 242
  • TABLE 81 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 242
  • TABLE 82 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 242
  • TABLE 83 NORTH AMERICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 242
  • TABLE 84 NORTH AMERICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 243
  • TABLE 85 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 243
  • TABLE 86 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 243
  • TABLE 87 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 244
  • TABLE 88 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 244
  • TABLE 89 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 244
  • TABLE 90 NORTH AMERICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 244
  • TABLE 91 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 245
  • TABLE 92 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 245
  • TABLE 93 NORTH AMERICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 245
  • TABLE 94 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 245
  • TABLE 95 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 246
  • TABLE 96 NORTH AMERICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 246
  • TABLE 97 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 246
  • TABLE 98 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 247
  • TABLE 99 NORTH AMERICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 247
  • TABLE 100 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 247
  • TABLE 101 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 248
  • TABLE 102 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 248
  • TABLE 103 NORTH AMERICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 248
  • TABLE 104 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 248
  • TABLE 105 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 106 NORTH AMERICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 107 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 108 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 109 NORTH AMERICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 110 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 111 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 112 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 250
  • TABLE 113 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 251
  • TABLE 114 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 251
  • TABLE 115 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 252
  • TABLE 116 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 252
  • TABLE 117 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 252
  • TABLE 118 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 252
  • TABLE 119 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 253
  • TABLE 120 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 253
  • TABLE 121 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 253
  • TABLE 122 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 253
  • TABLE 123 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 253
  • TABLE 124 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 254
  • TABLE 125 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 254
  • TABLE 126 U.S. TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 254
  • TABLE 127 U.S. BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 254
  • TABLE 128 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 255
  • TABLE 129 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 255
  • TABLE 130 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 255
  • TABLE 131 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 255
  • TABLE 132 U.S. ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 256
  • TABLE 133 U.S. SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 256
  • TABLE 134 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 256
  • TABLE 135 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 257
  • TABLE 136 U.S. ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 257
  • TABLE 137 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 257
  • TABLE 138 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 257
  • TABLE 139 U.S. UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 258
  • TABLE 140 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 258
  • TABLE 141 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 258
  • TABLE 142 U.S. PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 259
  • TABLE 143 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 259
  • TABLE 144 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 259
  • TABLE 145 U.S. UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 259
  • TABLE 146 U.S. LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 260
  • TABLE 147 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 260
  • TABLE 148 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 260
  • TABLE 149 U.S. ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 260
  • TABLE 150 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 261
  • TABLE 151 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 261
  • TABLE 152 U.S. UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 261
  • TABLE 153 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 261
  • TABLE 154 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 262
  • TABLE 155 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 262
  • TABLE 156 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 262
  • TABLE 157 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 262
  • TABLE 158 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 263
  • TABLE 159 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 263

LIST OF FIGURES

  • FIGURE 1 GLOBAL UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION 128
  • FIGURE 2 GLOBAL UTERINE CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 131
  • FIGURE 3 GLOBAL UTERINE CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 132
  • FIGURE 4 GLOBAL UTERINE CANCER DIAGNOSTIC MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 133
  • FIGURE 5 GLOBAL UTERINE CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 133
  • FIGURE 6 GLOBAL UTERINE CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 134
  • FIGURE 7 GLOBAL UTERINE CANCER DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID 136
  • FIGURE 8 GLOBAL UTERINE CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 138
  • FIGURE 9 GLOBAL UTERINE CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 140
  • FIGURE 10 GLOBAL UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION 144
  • FIGURE 11 GROWING AWARENESS OF UTERINE CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL UTERINE CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 145
  • FIGURE 12 INSTRUMENT BASED SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL UTERINE CANCER DIAGNOSTIC MARKET IN 2023 & 2030 145
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL UTERINE CANCER DIAGNOSTIC MARKET AND NORTH AMERICA IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 146
  • FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR GLOBAL UTERINE CANCER DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 147
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE UTERINE CANCER DIAGNOSTICS MARKET 160
  • FIGURE 16 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2022 168
  • FIGURE 17 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION) 169
  • FIGURE 18 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, CAGR (2023-2030) 169
  • FIGURE 19 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, LIFELINE CURVE 170
  • FIGURE 20 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2022 180
  • FIGURE 21 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2023-2030 (USD MILLION) 181
  • FIGURE 22 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2023-2030) 181
  • FIGURE 23 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE 182
  • FIGURE 24 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022 205
  • FIGURE 25 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 206
  • FIGURE 26 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 206
  • FIGURE 27 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 207
  • FIGURE 28 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2022 214
  • FIGURE 29 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 215
  • FIGURE 30 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 215
  • FIGURE 31 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 216
  • FIGURE 32 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 224
  • FIGURE 33 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 225
  • FIGURE 34 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 225
  • FIGURE 35 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 226
  • FIGURE 36 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 232
  • FIGURE 37 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY REGION (2022) 233
  • FIGURE 38 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2023) 233
  • FIGURE 39 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2023) 234
  • FIGURE 40 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2023) 234
  • FIGURE 41 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 237
  • FIGURE 42 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 238
  • FIGURE 43 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 238
  • FIGURE 44 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 239
  • FIGURE 45 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030) 239
  • FIGURE 46 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 288
  • FIGURE 47 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 289
  • FIGURE 48 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 289
  • FIGURE 49 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 290
  • FIGURE 50 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030) 290
  • FIGURE 51 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 494
  • FIGURE 52 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 495
  • FIGURE 53 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 495
  • FIGURE 54 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 496
  • FIGURE 55 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030) 496
  • FIGURE 56 SOUTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 680
  • FIGURE 57 SOUTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 681
  • FIGURE 58 SOUTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 681
  • FIGURE 59 SOUTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 682
  • FIGURE 60 SOUTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030) 682
  • FIGURE 61 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 723
  • FIGURE 62 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 724
  • FIGURE 63 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 724
  • FIGURE 64 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 725
  • FIGURE 65 MIDDLE EAST AND AFRICA UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030) 725
  • FIGURE 66 GLOBAL UTERINE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 856
  • FIGURE 67 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 857
  • FIGURE 68 EUROPE UTERINE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 858
  • FIGURE 69 ASIA-PACIFIC UTERINE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 859